
Prostate Cell News
Prostate Cell News is an online resource summarizing the latest prostate cell research.
Subscribe|Follow Us On
SPEN Inactivation Drives Resistance to Androgen Receptor Pathway Inhibitors in Metastatic Prostate Cancer
[Clinical Cancer Research] In real-world cohorts, loss of SPEN function across genomic, transcriptomic, and protein levels is associated with reduced benefit from androgen receptor pathway inhibitors therapy in metastatic prostate cancer.
Domain-Alteration Chimeras Rewire Oncogenic Complexes in Prostate Cancer
[Nature] Scientists described a novel therapeutic modality, domain-alteration chimeras, that rewire endogenous protein complexes by enforcing non-native domain–domain interactions.
First FDA Breakthrough Therapy Designation in PSMA PET Imaging Granted to Cu-64 SAR-bisPSMA in Biochemical Recurrence of Prostate Cancer
[Clarity Pharmaceuticals (PR Newswire)] Clarity Pharmaceuticals announced that the US FDA granted 64Cu-SAR-bisPSMA Breakthrough Therapy designation for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected recurrence based on elevated serum prostate-specific antigen level.
APOC1 Drives M2 Macrophage Polarization and Prostate Cancer Progression via PPARG-IL-10 and Is Targeted by α-NAD
[International Immunopharmacology] Researchers investigate the expression profile of apolipoprotein C1 (APOC1) in the prostate cancer microenvironment and elucidated its mechanistic role in modulating macrophage polarization to promote tumor progression.
Methionine Restriction Inhibits EZH2-Mediated GSDMD Methylation to Promote Pyroptosis in Prostate Cancer
[Proceedings of the National Academy of Sciences of the United States of America] Researchers identified EZH2 as a posttranslational suppressor of pyroptosis through direct methylation of GSDMD. They revealed that EZH2 inhibition triggered GSDMD-dependent pyroptosis in prostate cancer cells.
XPO5 Regulates Ferroptosis via MITF-ACSL4 Signaling to Drive CRPC Progression and Serves As a Druggable Target
[Cell Reports Medicine] Researchers elucidated the molecular mechanism by which exportin 5 (XPO5) promotes prostate cancer (PCa) progression and developed the small-molecule degrader targeting XPO5 for the targeted treatment of PCa.
Metabolic Rewiring That Protects against Ferroptosis Underlies Resistance to CDK4/6 Inhibition in Prostate Cancer
[Cell Death & Disease] The authors demonstrated that acquired resistance to the CDK4/6 inhibitor ribociclib in prostate cancer cells is driven by enhanced mitochondrial metabolic activity and increased dependence on fatty acid β-oxidation for energy production through the TCA cycle.
A Lactate-Fatty Acid Loop Drives Prostate Cancer Bone Colonization by Mediating Metabolic Interplay between Tumor Cells and Osteoblasts
[Nature Communications] Scientists showed that prostate cancer cells metabolically adapt to the bone microenvironment by utilizing bone-cell-derived lactate as an alternative nutrient source.
Tumor-Associated Macrophages in Prostate, Bladder, and Renal Cancer Metastasis: Mechanisms, and Therapeutic Implications
[Critical Reviews in Oncology/Hematology] The authors synthesize recent mechanistic insights to provide a conceptual framework of the tumor-associated macrophage-driven metastatic cascade.
Johnson & Johnson Reports 75% Tumor Response Rate in Advanced Prostate Cancer with JNJ-6143, a First-in-Class RIPTAC™ Molecule
[Johnson & Johnson] Johnson & Johnson announced Phase I results for JNJ-6143, an investigational once-daily oral Regulated Induced Proximity Targeting Chimera small molecule, in patients with advanced prostate cancer who had received multiple prior treatments. Among patients with measurable disease, 75% had a confirmed complete or partial response.
Syncromune® Reports Long-Term Data from Phase I Study in Metastatic Prostate Cancer with Investigational SYNC-T Therapy SV-102
[Syncromune, Inc.] Syncromune, Inc. announced updated overall survival results from a Phase I trial of its investigational SYNC-T Therapy SV-102 in patients with metastatic prostate cancer.
Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
[Pfizer, Inc.] Pfizer, Inc. announced that the US FDA has expanded approval of TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) to the treatment of men with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair gene mutations.
Published since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing of prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.

Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
